


# Patent Claims

1. Use of one or more of the compounds of the formula I



in which

$\text{Ar}^1$  denotes phenyl, naphthyl, biphenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by  $\text{R}^1$ ,

$\text{Ar}^2$  denotes phenyl, naphthyl, biphenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by  $\text{R}^2$ ,

$\text{Y}$  denotes O, S,  $\text{CH-NO}_2$ ,  $\text{C(CN)}_2$  or  $\text{N-R}^4$ ,

$\text{Z}$  denotes  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{CH}_2-(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n-\text{CHA}-$ ,  $-\text{CHA}-$ ,  $(\text{CH}_2)_n-$ ,  $-\text{C(=O)}-$ ,  $-\text{CH(OH)}-$ ,  $-(\text{CHA})_n\text{O}-$ ,  $-(\text{CH}_2)_n\text{O}-$ ,  $-\text{O}(\text{CHA})_n-$ ,  $-\text{O}(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n\text{S}-$ ,  $-\text{S}(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n\text{NH}-$ ,  $-\text{NH}(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n\text{NA}-$ ,  $-\text{NA}(\text{CH}_2)_n-$ ,  $-\text{CHHal}-$  or  $-\text{C(Hal)}_2-$ ,

Het denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,

$\text{R}^1$ ,  $\text{R}^2$ , independently of one another, denote A,  $\text{Ar}'$ ,  $\text{OR}^3$ ,  $\text{SR}^3$ ,  $\text{OAr}'$ ,  $\text{SAr}'$ ,  $\text{N(R}^3)_2$ ,  $\text{NHAr}'$ , Hal,  $\text{NO}_2$ , CN,  $(\text{CH}_2)_n\text{COOR}^3$ ,  $(\text{CH}_2)_n\text{CON(R}^3)_n$ ,  $\text{COR}^3$ ,  $\text{S(O)}_m\text{A}$ ,  $\text{S(O)}_m\text{Ar}'$ ,  $\text{NHCOA}$ ,  $\text{NHCOAr}'$ ,  $\text{NHSO}_m\text{A}$ ,  $\text{NHSO}_m\text{Ar}'$ ,  $\text{SO}_m\text{N(R}^3)_2$ ,  $-\text{O}-(\text{CH}_2)_n-\text{N(R}^3)_2$ ,  $\text{O}(\text{CH}_2)_n\text{NHR}^3$ ,  $\text{O}(\text{CH}_2)_n\text{NA}_2$ ,  $\text{O}(\text{CH}_2)_n\text{C(CH}_3)_2(\text{CH}_2)_n\text{N(R}^3)_2$ ,  $\text{NH}(\text{CH}_2)_n(\text{CH}_3)_2(\text{CH}_2)_n\text{N(R}^3)_2$ ,  $\text{O}(\text{CH}_2)_n\text{N(R}^3)\text{SO}_m\text{A}$ ,  $\text{O}(\text{CH}_2)_n\text{N(R}^3)\text{SO}_m\text{N(R}^3)\text{A}$ ,  $\text{O}(\text{CH}_2)_n\text{N(R}^3)\text{SO}_m\text{Ar}'$ ,  $(\text{CH}_2)_n\text{N(R}^3)\text{SO}_m\text{A}$ ,  $(\text{CH}_2)_n\text{N(R}^3)\text{SO}_m\text{N(R}^3)\text{A}$ ,  $(\text{CH}_2)_n\text{N(R}^3)\text{SO}_m\text{Ar}'$ ,  $\text{O}(\text{CH}_2)_n\text{SO}_m\text{A}$ ,  $\text{O}(\text{CH}_2)_n\text{SO}_m\text{N(R}^3)\text{A}$ ,

$O(CH_2)_nSO_mAr'$ ,  $(CH_2)_nSO_mA$ ,  $(CH_2)_nSO_mN(R^3)A$ ,  
 $(CH_2)_nSO_mAr'$ ,  $-NH-(CH_2)_n-NH_2$ ,  $-NH-(CH_2)_n-NHA$ ,  $-NH-$   
 $(CH_2)_n-NA_2$ ,  $-NA-(CH_2)_n-NH_2$ ,  $-NA-(CH_2)_n-NHA$ ,  $-NA-(CH_2)_n-$   
 $NA_2$ ,  $-O-(CH_2)_n-Het^1$  or  $Het^1$ ,

5  $R^3$  denotes H, A or  $(CH_2)_nAr'$ ,

$R^4$  denotes H, CN, OH, A,  $(CH_2)_mAr'$ ,  $COR^3$ ,  $COAr'$ ,  $S(O)_mA$  or  $S(O)_mAr'$ ,

10  $Ar'$  denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by A, Ph, OH, OA, SH, SA, OPh, SPh,  $NH_2$ , NHA,  $NA_2$ , NHPH, Hal,  $NO_2$ , CN,  $(CH_2)_nCOOH$ ,  $(CH_2)_nCOOA$ ,  $(CH_2)_nCONH_2$ ,  $(CH_2)_nCONHA$ , CHO, COA,  $S(O)_mA$ ,  $S(O)_mPh$ , NHCOA, NHCOPh,  $NHSO_2A$ ,  $NHSO_2Ph$  or  $SO_2NH_2$ ,

15 Ph denotes phenyl which is unsubstituted or mono-, di- or tri-substituted by A, Hal, CN, COOR, COOH,  $NH_2$ ,  $NO_2$ , OH or OA,

20  $Het^1$  denotes a monocyclic saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN,  $(CH_2)_nOH$ ,  $(CH_2)_nHal$ ,  $NH_2$ ,  $=NH$ ,  $=N-OH$ ,  $=N-OA$  and/or carbonyl oxygen ( $=O$ ),

25 A denotes alkyl having 1 to 10 C atoms, where 1-7 H atoms may also be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2, 3, 4 or 5,

30 m denotes 0, 1 or 2,

and pharmaceutically usable derivatives, solvates, salts and stereo-  
 isomers thereof, including mixtures thereof in all ratios, for the pre-  
 35 paration of a medicament for the prophylaxis and/or treatment of  
 diseases in which the inhibition, regulation and/or modulation of  
 kinase signal transduction plays a role.


- 5
2. Use according to Claim 1, characterised in that the disease is (are) caused, mediated and/or propagated by tyrosine and/or Raf kinase(s).
- 10
3. Use according to Claim 2, characterised in that the disease is caused, mediated and/or propagated by A-Raf, B-Raf and/or Raf-1 kinase.
- 15
4. Use according to one or more of Claims 1 to 3, characterised in that the disease is a hyperproliferative disease.
- 20
5. Use according to Claim 4, characterised in that the disease is a cancer-like disease.
- 25
6. Use according to Claim 5, characterised in that the disease is brain cancer, lung cancer, squamous epithelium cancer, bladder cancer, stomach cancer, pancreatic cancer, liver cancer, kidney cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia or acute leukaemia.
- 30
7. Use according to Claim 4, characterised in that the disease is not cancer-like.
- 35
8. Use according to Claim 7, characterised in that the disease is psoriasis, endometriosis, scarring or benign prostate hyperplasia.
9. Use according to one or more of Claims 1 to 3, characterised in that the disease is an inflammation, arthritis, *Helicobacter pylori* infection, influenza A, an immunological disease, an autoimmune dis-

ease or an immunodeficiency disease.

10. Use according to one or more of Claims 1 to 9, characterised in that a compound of the formula I is employed in which

Z denotes  $-\text{CH}_2-(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n-\text{CHA}$ ,  $-\text{CHA}-\text{O}-$  or  $-\text{O}-$ , and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

11. Compounds general formula VI



in which

$\text{Ar}^1$  denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by  $\text{R}^1$ ,

$\text{Ar}^2$  denotes phenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by  $\text{R}^2$ ,

Y denotes O,

Z denotes  $-\text{O}-$ ,  $-\text{CH}_2-(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n-\text{CHA}-$ ,  $-\text{CHA}-(\text{CH}_2)_n-$ ,  $-\text{C}(=\text{O})-$ ,  $-\text{CH}(\text{OH})-$ ,  $-\text{CH}(\text{OA})-$ ,  $-(\text{CH}_2)_n\text{O}-$ ,  $-\text{O}(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n\text{NH}-$  or  $-\text{NH}(\text{CH}_2)_n-$ ,

Het denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,

$\text{R}^1$ ,  $\text{R}^2$ , independently of one another, denote A,  $\text{OR}^3$ , Hal,  $\text{NO}_2$ , CN,  $\text{S}(\text{O})_m\text{A}$ ,  $\text{O}(\text{CH}_2)_n\text{NA}_2$  or  $\text{Het}^1$ ,

$\text{R}^3$  denotes H or A,

$\text{Het}^1$  denotes a monocyclic saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN,  $(\text{CH}_2)_n\text{OH}$ ,

$(\text{CH}_2)_n\text{Hal}$ ,  $\text{NH}_2$ ,  $=\text{NH}$ ,  $=\text{N-OH}$ ,  $=\text{N-OA}$  and/or carbonyl oxygen ( $=\text{O}$ ),

A denotes alkyl having 1 to 10 C atoms, where 1-7 H atoms may also be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, or 2,

m denotes 0, 1 or 2,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

12. Compounds of the formula I according to Claim 1, characterised in that these have the following structures:

1-(2-methoxy-5-trifluoromethylphenyl)-3-(5-pyridin-4-ylmethyl-1,3,4-thiadiazol-2-yl)urea,

1-(5-chloro-2-methoxy-4-methylphenyl)-3-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethoxyphenyl)urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethanesulfonylphenyl)urea,

1-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-(2-methoxy-5-trifluoromethylphenyl)urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-p-tolylurea,

1-(2-methoxy-5-methylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chloro-4-methylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(5-chloro-2-methylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chloro-2-methylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(5-chloro-2-methoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(4-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-(2-methoxyphenyl)urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(4-trifluoromethoxyphenyl)urea,

1-(4-fluoro-3-trifluoromethylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(2,3-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-(4-trifluoromethoxyphenyl)urea,

1-[5-(2,3-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-(2-trifluoromethoxyphenyl)urea,

1-(5-chloro-2,4-dimethoxyphenyl)-3-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]urea,

1-(2,4-dimethoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chloro-4-methoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[2-(2-dimethylaminoethoxy)-5-trifluoromethylphenyl]-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-[4-chloro-5-methyl-2-(piperidin-4-yloxy)phenyl]-3-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]urea,

1-(2-methoxy-5-trifluoromethylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(5-chloro-2-methoxy-4-methylphenyl)-3-(5-pyridin-4-ylmethyl-  
1,3,4-thiadiazol-2-yl)urea,

1-(5-pyridin-4-ylmethyl-1,3,4-thiadiazol-2-yl)-3-(3-trifluorometh-  
oxyphenyl)urea,

5

1-(5-chloro-2-methoxy-4-methylphenyl)-3-[5-(1-phenylethyl)-  
1,3,4-thiadiazol-2-yl]urea,

1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethoxy-  
phenyl)urea,

10

1-(2-methoxy-5-trifluoromethylphenyl)-3-[5-(1-phenylpropyl)-  
1,3,4-thiadiazol-2-yl]urea,

1-(5-chloro-2-methoxy-4-methylphenyl)-3-[5-(4-chlorophenoxy-  
methyl)-1,3,4-thiadiazol-2-yl]urea,

15

1-[5-(4-chlorophenoxyethyl)-1,3,4-thiadiazol-2-yl]-3-(3-tri-  
fluoromethoxyphenyl)urea,

1-[4-chloro-2-(2-dimethylaminoethoxy)-5-methylphenyl]-3-[5-(1-  
phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

20

1-[4-chloro-2-(2-dimethylaminoethoxy)-5-methylphenyl]-3-[5-  
(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(3,4-dimethoxybenzyl)-1,3,4-thiadiazol-2-yl]-3-[2-(2-di-  
methylaminoethoxy)-5-trifluoromethylphenyl]urea,

25

1-(2-methoxy-5-methylphenyl)-3-[5-(1-phenylpropyl)-1,3,4-thia-  
diazol-2-yl]urea,

1-(2,5-dimethoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-  
yl]urea,

30

1-(2,5-dichlorophenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-  
urea,

1-[5-(hydroxyphenylmethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoro-  
methylphenyl)urea,

1-(2-methoxy-5-methylphenyl)-3-[5-(2-methyl-1-phenylpropyl)-  
1,3,4-thiadiazol-2-yl]urea,

35

1-(2-fluoro-5-trifluoromethylphenyl)-3-(5-pyridin-4-ylmethyl-1,3,4-  
thiadiazol-2-yl)urea,

1-(4-fluoro-3-trifluoromethylphenyl)-3-(5-pyridin-4-ylmethyl-1,3,4-thiadiazol-2-yl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-m-tolylurea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-m-tolylurea,

1-(3-chloro-4-methylphenyl)-3-[5-(2-methyl-1-phenylpropyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chlorophenyl)-3-[5-(3,4-dimethoxyphenoxy)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chlorophenyl)-3-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chlorophenyl)-3-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}urea,

1-(5-chloro-2,4-dimethoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

1-(3-chlorophenyl)-3-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(3,4-dimethoxyphenylamino)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxy)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)urea,

1-[5-(4-chlorophenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-(4-fluoro-3-trifluoromethylphenyl)urea,

1-(5-chloro-2-methoxyphenyl)-3-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}urea,

1-(5-chloro-2-methoxyphenyl)-3-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]urea,

1-(5-chloro-2-methoxyphenyl)-3-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]urea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-(3-trifluoromethylphenyl)urea,



1-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenylamino)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxy)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxy)-1,3,4-thiadiazol-2-yl]-3-(4-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-(3-fluoro-5-trifluoromethylphenyl)urea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-(3-fluoro-5-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-5-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-(4-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-(4-fluoro-3-trifluoromethylphenyl)urea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}-3-(2-fluoro-5-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-{5-[2-(3,4-dimethoxyphenyl)ethyl]-1,3,4-thiadiazol-2-yl}urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-[5-(3,4-dimethoxybenzylamino)-1,3,4-thiadiazol-2-yl]urea,

1-(3,5-bistrifluoromethylphenyl)-3-[5-(3,4-dimethoxyphenyl-  
amino)-1,3,4-thiadiazol-2-yl]urea,

1-(3,5-bistrifluoromethylphenyl)-3-[5-(3,4-dimethoxybenzoyl)-  
1,3,4-thiadiazol-2-yl]urea,

5 1-(3,5-bistrifluoromethylphenyl)-3-{5-[2-(3,4-dimethoxyphenyl)-  
ethyl]-1,3,4-thiadiazol-2-yl}urea,

1-(3,5-bistrifluoromethylphenyl)-3-[5-(3,4-dimethoxybenzyl-  
amino)-1,3,4-thiadiazol-2-yl]urea,

10 1-(3-chlorophenyl)-3-[5-(pyridin-4-yloxy)-1,3,4-thiadiazol-2-yl]-  
urea,

1-[5-(pyridin-4-yloxy)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethyl-  
phenyl)urea,

15 1-(4-fluoro-3-trifluoromethylphenyl)-3-[5-(pyridin-4-yloxy)-1,3,4-  
thiadiazol-2-yl]urea,

1-(2-fluoro-3-trifluoromethylphenyl)-3-[5-(pyridin-4-yloxy)-1,3,4-  
thiadiazol-2-yl]urea,

20 1-(2-fluoro-5-trifluoromethylphenyl)-3-[5-(pyridin-4-yloxy)-1,3,4-  
thiadiazol-2-yl]urea,

1-(3,5-bistrifluoromethylphenyl)-3-[5-(pyridin-4-yloxy)-1,3,4-thia-  
diazol-2-yl]urea,

25 1-(5-chloro-2-methoxyphenyl)-3-[5-(4-chlorophenoxymethyl)-  
1,3,4-thiadiazol-2-yl]urea,

1-[5-(4-chlorophenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoro-  
methylphenyl)urea,

30 1-[5-(3,4-dimethoxybenzoyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoro-  
methylphenyl)- urea,

1-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-thiadiazol-2-yl]-3-m-  
tolylurea,

1-(3-chlorophenyl)-3-[5-(3,4-dimethoxyphenoxymethyl)-1,3,4-  
thiadiazol-2-yl]urea,

35 1-(5-chloro-2-methoxyphenyl)-3-[5-(3,4-dimethoxyphenoxy-  
methyl)-1,3,4-thiadiazol-2-yl]urea,

1-[5-(3,4-dimethoxyphenoxy)methyl]-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxy)methyl]-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxy)methyl]-1,3,4-thiadiazol-2-yl]-3-(3-fluoro-5-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxy)methyl]-1,3,4-thiadiazol-2-yl]-3-(4-fluoro-3-trifluoromethylphenyl)urea,

1-[5-(3,4-dimethoxyphenoxy)methyl]-1,3,4-thiadiazol-2-yl]-3-(2-fluoro-5-trifluoromethylphenyl)urea,

1-(4-chloro-3-trifluoromethylphenyl)-3-[5-(3,4-dimethoxyphenoxy)methyl]-1,3,4-thiadiazol-2-yl]urea,

1-(3,5-bistrifluoromethylphenyl)-3-[5-(3,4-dimethoxyphenoxy)methyl]-1,3,4-thiadiazol-2-yl]urea,

(S)-1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)urea,

(R)-1-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]-3-(3-trifluoromethylphenyl)urea,

(S)-1-(5-chloro-2-methoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea enantiomer,

(R)-1-(5-chloro-2-methoxyphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,


(S)-1-(4-fluoro-3-trifluoromethylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea,

(R)-1-(4-fluoro-3-trifluoromethylphenyl)-3-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]urea

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

13. Process for the preparation of the compounds according to Claim 11 and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, characterised in that

a) a compound of the formula II



in which  $\text{Y}$ ,  $\text{Z}$  and  $\text{Ar}^2$  each have the same meaning as in the compound according to Claim 11 to be prepared,  
and  $\text{L}$  denotes  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{I}$  or a free or reactively functionally modified  $\text{OH}$  group,


is reacted with a compound of the formula III



in which  $\text{Ar}^1$  has the same meaning as in the compound according to Claim 11 to be prepared,


or

c) a compound of the formula IV



in which  $\text{Ar}^1$  has the same meaning as in the compound according to Claim 11 to be prepared,

is reacted with a compound of the formula V



10 in which Z and Ar<sup>2</sup> each have the same meaning as in the compound according to Claim 11 to be prepared,

and/or

15 a base or acid of the formula I is converted into one of its salts.

14. Medicament comprising at least one compound according to Claim 11 and/or one of its pharmaceutically usable derivatives, salts, solvates and stereoisomers, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
- 20

15. Set (kit) consisting of separate packs of
- 25 a) an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
- b) an effective amount of a further medicament active ingredient.
- 30